A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors

NCT06726369 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: MK-6204 (SKB535) for Injection

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.